Treatment outcomes of multidrug-resistant tuberculosis patients in China: a meta-analysis_Chinese Journal of Evidence-Based Medicine

Authors：

FANG Shilin ¹ ,  WANG Yun ^1,2 , LU Xiaolong ¹ , ZHANG Qiuyu ¹

1. School of Medicine and Health Management, Guizhou Medical University, Guiyang 550025, P.R.China;
2. Key Laboratory of Environmental Pollution Monitoring and Disease Control, Ministry of Education, Guizhou Medical University, Guiyang 550025, P.R.China;

Corresponding author：

WANG Yun, Email: 441334899@qq.com

Keywords：

Multidrug-resistant tuberculosis; Treatment outcome; Meta-analysis

DOI：

10.7507/1672-2531.202106209

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically review the treatment outcomes of multidrug-resistant tuberculosis (MDR-TB) patients, and to provide evidence for treatment. Methods Databases including PubMed, Web of Science, ScienceDirect, CNKI, WanFang Data and VIP were electronically searched to collect literature related to MDR-TB from inception to April 28^th, 2021. Two reviewers independently screened literature, extracted data, and assessed the risk of bias of the included studies. Meta-analysis was then performed using R 4.0.5 software, subgroup and meta-regression analyses were performed based on sample size, survey time, etc. Results A total of 36 studies involving 7 981 patients were included. The results of meta-analysis showed that the overall treatment success rate of MDR-TB patients was 60% (95%CI 56% to 63%). The subgroup analysis showed that the treatment success rates of MDR-TB were 49% (95%CI 41% to 58%) from 1992 to 2010, 62% (95%CI 58% to 65%) from 2011 to 2015, and 62% (95%CI 55% to 68%) from 2016 to 2020; those with sample size above 100 and less than 100 were 60% (95%CI 55% to 65%) and 59% (95%CI 54% to 63%), respectively; those with average age above 45 and less than 45 were 58% (95%CI 51% to 65%) and 56% (95%CI 53% to 59%); those of MDR-TB were 63% (95%CI 57% to 68%) in central China, 63% (95%CI 52% to 73%) in the Northwest, 60% (95%CI 55% to 65%) in the Southeast, and 53% (95%CI 48% to 58%) in the Northeast. Conclusions The overall success rate of treatment for MDR-TB patients in China is low. Due to the limited quantity and quality of included studies, more high-quality studies are required to verify the above conclusions.

Citation： FANG Shilin, WANG Yun, LU Xiaolong, ZHANG Qiuyu. Treatment outcomes of multidrug-resistant tuberculosis patients in China: a meta-analysis. Chinese Journal of Evidence-Based Medicine, 2021, 21(11): 1316-1324. doi: 10.7507/1672-2531.202106209 Copy

1.	范琳, 刘一典, 肖和平. 国内《耐药结核病化学治疗指南(2019年)》与相关共识的特色及要点分析. 中国防痨杂志, 2020, 42(2): 91-94.
2.	李志鹏, 盛宇超, 竺丽梅, 等. 徐州市和赣州市耐多药结核病患者纳入治疗的影响因素分析. 中国预防医学杂志, 2020, 21(8): 913-917.
3.	马慧芬, 孔鹏, 孟庆跃. 耐多药肺结核治疗管理模式现状. 医学与哲学, 2012, 33(12): 74-76.
4.	World Health Organization. Global tuberculosis report (2020-10-15). Available at: https://www.who.int/publications/i/item/9789240013131.
5.	周颖, 黄奕祥. 中国耐多药肺结核患者治疗结局的Meta分析. 热带医学杂志, 2016, 16(3): 325-328.
6.	罗杰, 冷卫东. 《系统评价/Meta分析理论与实践》. 中国循证心血管医学杂志, 2013, 5(2): 115.
7.	刘志辉, 刘玉美, 伍慧仪, 等. 广州地区251例耐多药结核病例分析. 实用医学杂志, 2005, 21(15): 1712-1714.
8.	郝晓晖, 姚岚, 唐神结, 等. 初治耐多药肺结核临床疗效及其转归队列分析. 中华传染病杂志, 2012, 30(3): 157-161.
9.	杜雨华, 苏汝钊, 周惠贤, 等. 116例耐多药肺结核治疗转归情况影响因素分析. 中国防痨杂志, 2012, 34(1): 19-22.
10.	刘金玲, 罗凯, 崔兰英. 标准化疗方案治疗耐多药肺结核的疗效分析. 当代医学, 2013, (16): 77.
11.	覃红娟, 谭守勇, 邝浩斌, 等. 耐多药肺结核患者住院与门诊治疗对疗效的影响. 实用医学杂志, 2013, 29(23): 3811-3814.
12.	Tang S, Tan S, Yao L, et al. Risk factors for poor treatment outcomes in patients with MDR-TB and XDR-TB in China: retrospective multi-center investigation. PLoS One, 2013, 8(12): e82943.
13.	孔雯, 刘巧, 陆伟, 等. 标准化耐多药肺结核化疗方案的不良反应及治疗转归情况分析. 中华疾病控制杂志, 2014, 18(7): 610-612.
14.	丁晓艳, 许卫国, 竺丽梅, 等. 175例耐多药肺结核患者治疗转归情况分析. 中国防痨杂志, 2014, 36(4): 238-243.
15.	费宗伍. 230例耐多药结核病患者的发现和治疗情况的研究. 临床医药文献电子杂志, 2014, (4): 522-523.
16.	郭苏珊. 75例耐多药肺结核治疗副作用及转归分析. 现代医院, 2015, (3): 68-69,72.
17.	屈亚虹, 朱宁, 马振亚, 等. 开封市耐多药肺结核治疗管理效果及影响因素分析. 中国防痨杂志, 2015, 37(1): 97-99.
18.	张海清, 孙建胜, 吴云亮, 等. 128例耐多药肺结核患者的转归分析. 徐州医学院学报, 2015, (8): 534-536.
19.	田晓梅, 石峰, 王晓林, 等. 宁夏耐多药/广泛耐药肺结核患者的发现及治疗效果评价. 宁夏医学杂志, 2015, 37(4): 364-366.
20.	马俊锋, 王小平, 陆峰, 等. 南通市全球基金耐多药结核病项目患者治疗情况分析. 南京医科大学学报(自然科学版), 2015, 35(5): 757-760.
21.	李莉, 孙建胜, 吴云亮. 徐州市完成全球基金耐多药结核病项目全程治疗的耐多药结核病患者治疗效果的影响因素分析. 实用心脑肺血管病杂志, 2015, (7): 50-54.
22.	张志进. 如皋市耐多药肺结核患者发现, 治疗转归情况分析. 江苏预防医学, 2016, 27(4): 498-499.
23.	刘凡平, 张晨钰, 王云, 等. 全球基金标准化疗方案治疗耐多药肺结核临床疗效评价. 河北医药, 2016, 38(7): 1060-1062.
24.	周美兰, 杜义祥, 王坚杰, 等. 武汉市耐多药肺结核患者防治模式效果分析. 中国防痨杂志, 2016, 38(11): 918-924.
25.	代晓琦, 阮云洲, 李仁忠, 等. “医防合作”模式下实施DOT对耐多药肺结核患者不同治疗转归的分析. 中国防痨杂志, 2016, 38(11): 929-933.
26.	易恒仲, 罗丹霖, 唐志冈, 等. 湖南省全球基金耐多药结核病项目患者治疗情况分析. 中国热带医学, 2017, 17(3): 244-247.
27.	Lu P, Liu Q, Martinez L, et al. Time to sputum culture conversion and treatment outcome of patients with multidrug-resistant tuberculosis: a prospective cohort study from urban China. Eur Respir J, 2017, 49(3): 1601558.
28.	Alene KA, Yi H, Viney K, et al. Treatment outcomes of patients with multidrug-resistant and extensively drug resistant tuberculosis in Hunan province, China. BMC Infect Dis, 2017, 17(1): 573.
29.	林彬, 杨芳玲, 王先化, 等. 克拉玛依市与昌吉州耐多药肺结核转归分析. 预防医学论坛, 2017, 23(2): 107-108,111.
30.	Xu C, Pang Y, Li R, et al. Clinical outcome of multidrug-resistant tuberculosis patients receiving standardized second-line treatment regimen in China. J Infect, 2018, 76(4): 348-353.
31.	Lv L, Li T, Xu K, et al. Sputum bacteriology conversion and treatment outcome of patients with multidrug-resistant tuberculosis. Infect Drug Resist, 2018, 11: 147-154.
32.	Zhang L, Meng Q, Chen S, et al. Treatment outcomes of multidrug-resistant tuberculosis patients in Zhejiang, China, 2009-2013. Clin Microbiol Infect, 2018, 24(4): 381-388.
33.	Fan YM, Ding SP, Bao ZJ, et al. Prognostic factors for treatment success in patients with multidrug-resistant tuberculosis in China. Int J Tuberc Lung Dis, 2018, 22(3): 300-305.
34.	包昌琳, 易恒仲, 唐益, 等. 耐多药肺结核患者化学治疗疗效及其影响因素分析. 中国防痨杂志, 2018, 40(5): 525-530.
35.	陈壮濠, 林健雄, 李鸿槟, 等. 汕头市耐多药结核病患者治疗情况分析. 临床肺科杂志, 2018, 23(10): 1850-1853.
36.	Chen Y, Yuan Z, Shen X, et al. Time to multidrug-resistant tuberculosis treatment initiation in association with treatment outcomes in Shanghai, China. Antimicrob Agents Chemother, 2018, 62(4): e02259-17.
37.	Li Q, Shi CX, Lu M, et al. Treatment outcomes of multidrug-resistant tuberculosis in Hangzhou, China, 2011 to 2015. Medicine (Baltimore), 2020, 99(30): e21296.
38.	Zheng XB, Diwan VK, Zhao Q, et al. Treatment quality and outcome for multidrug-resistant tuberculosis patients in four regions of China: a cohort study. Infect Dis Poverty, 2020, 9(1): 97.
39.	蔡春葵, 杨连军, 王申莲, 等. 316例耐多药肺结核患者的治疗结果分析. 中国医药指南, 2020, 18(22): 41-42.
40.	简丽萍, 郭子玉, 邓笑媚, 等. 耐多药肺结核疗效影响因素的研究. 中国医药科学, 2020, 10(13): 191-194.
41.	Liu Q, Yang D, Qiu B, et al. Drug resistance gene mutations and treatment outcomes in MDR-TB: a prospective study in Eastern China. PLoS Negl Trop Dis, 2021, 15(1): e0009068.
42.	Zhang MW, Zhou L, Zhang Y, et al. Treatment outcomes of patients with multidrug and extensively drug-resistant tuberculosis in Zhejiang, China. Eur J Med Res, 2021, 26(1): 31.
43.	张梦娴, 杨成凤, 叶建君, 等. 1447例耐多药肺结核患者治疗转归队列分析. 公共卫生与预防医学, 2020, 31(3): 68-72.
44.	Arnold A, Cooke GS, Kon OM, et al. Drug resistant TB: UK multicentre study (DRUMS): treatment, management and outcomes in London and West Midlands 2008-2014. J Infect, 2017, 74(3): 260-271.
45.	Riccardi N, Saderi L, Borroni E, et al. Therapeutic strategies and outcomes of MDR and pre-XDR-TB in Italy: a nationwide study. Int J Tuberc Lung Dis, 2021, 25(5): 395-399.
46.	Henry B, Revest M, Dournon N, et al. Preliminary favorable outcome for medically and surgically managed extensively drug-resistant tuberculosis, France, 2009-2014. Emerg Infect Dis, 2016, 22(3): 518-521.
47.	Eshetie S, Alebel A, Wagnew F, et al. Current treatment of multidrug resistant tuberculosis in Ethiopia: an aggregated and individual patients' data analysis for outcome and effectiveness of the current regimens. BMC Infect Dis, 2018, 18(1): 486.
48.	Alemu A, Bitew ZW, Worku T. Poor treatment outcome and its predictors among drug-resistant tuberculosis patients in Ethiopia: a systematic review and meta-analysis. Int J Infect Dis, 2020, 98: 420-439.
49.	Alene KA, Viney K, McBryde ES, et al. Treatment outcomes in patients with multidrug-resistant tuberculosis in north-west Ethiopia. Trop Med Int Health, 2017, 22(3): 351-362.
50.	Ahmed A, Mekonnen D, Shiferaw AM, et al. Incidence and determinants of tuberculosis infection among adult patients with HIV attending HIV care in north-east Ethiopia: a retrospective cohort study. BMJ Open, 2018, 8(2): e016961.
51.	中华人民共和国国务院办公厅. 全国结核病防治规划(2011-2015). Available at: http://www.gov.cn/zwgk/2011-12/06/content_2012869.htm.
52.	中华人民共和国国务院办公厅. 《“十三五”全国结核病防治规划》. Available at: http://www.gov.cn/xinwen/2017-02/16/content_5168549.htm.
53.	邝浩斌, 谢育红, 冯治宇, 等. 2014-2019年广州市耐多药肺结核管理策略实施效果分析. 中国防痨杂志, 2021, 43(2): 113-118.
54.	赵秀娟, 刘琳, 吴兴勇, 等. 海南省369例耐多药肺结核患者流行病学特征分析. 海南医学院学报, 2021. DOI: 10.13210/j.cnki.jhmu.20210413.002.
55.	王云霞, 郑娟娟, 张娟娟, 等. 2011-2018年宝安区肺结核患者耐多药的影响因素分析. 预防医学, 2021, 33(7): 701-703.
56.	全国第五次结核病流行病学抽样调查技术指导组, 全国第五次结核病流行病学抽样调查办公室. 2010年全国第五次结核病流行病学抽样调查报告. 中国防痨杂志, 2012, 34(8): 485-508.
57.	陕俊玲, 薛王谦, 韩亚男. 涂阳肺结核139例患者分枝杆菌培养及药敏分析. 中国药物与临床, 2013, 13(z1): 10-11.
58.	李秀杰. 172例耐多药结核病患者特征及治疗转归的影响因素分析. 中国现代医生, 2019, 57(7): 30-32.
59.	李雪, 李楠楠, 任斐, 等. 耐多药肺结核合并糖尿病的临床特点及治疗结局. 中国热带医学, 2021.
60.	周银发, 张山鹰, 柳珍妮, 等. 242例耐多药结核病患者特征及治疗转归的影响因素分析. 中国防痨杂志, 2017, 39(11): 1218-1222.

1. 范琳, 刘一典, 肖和平. 国内《耐药结核病化学治疗指南(2019年)》与相关共识的特色及要点分析. 中国防痨杂志, 2020, 42(2): 91-94.
2. 李志鹏, 盛宇超, 竺丽梅, 等. 徐州市和赣州市耐多药结核病患者纳入治疗的影响因素分析. 中国预防医学杂志, 2020, 21(8): 913-917.
3. 马慧芬, 孔鹏, 孟庆跃. 耐多药肺结核治疗管理模式现状. 医学与哲学, 2012, 33(12): 74-76.
4. World Health Organization. Global tuberculosis report (2020-10-15). Available at: https://www.who.int/publications/i/item/9789240013131.
5. 周颖, 黄奕祥. 中国耐多药肺结核患者治疗结局的Meta分析. 热带医学杂志, 2016, 16(3): 325-328.
6. 罗杰, 冷卫东. 《系统评价/Meta分析理论与实践》. 中国循证心血管医学杂志, 2013, 5(2): 115.
7. 刘志辉, 刘玉美, 伍慧仪, 等. 广州地区251例耐多药结核病例分析. 实用医学杂志, 2005, 21(15): 1712-1714.
8. 郝晓晖, 姚岚, 唐神结, 等. 初治耐多药肺结核临床疗效及其转归队列分析. 中华传染病杂志, 2012, 30(3): 157-161.
9. 杜雨华, 苏汝钊, 周惠贤, 等. 116例耐多药肺结核治疗转归情况影响因素分析. 中国防痨杂志, 2012, 34(1): 19-22.
10. 刘金玲, 罗凯, 崔兰英. 标准化疗方案治疗耐多药肺结核的疗效分析. 当代医学, 2013, (16): 77.
11. 覃红娟, 谭守勇, 邝浩斌, 等. 耐多药肺结核患者住院与门诊治疗对疗效的影响. 实用医学杂志, 2013, 29(23): 3811-3814.
12. Tang S, Tan S, Yao L, et al. Risk factors for poor treatment outcomes in patients with MDR-TB and XDR-TB in China: retrospective multi-center investigation. PLoS One, 2013, 8(12): e82943.
13. 孔雯, 刘巧, 陆伟, 等. 标准化耐多药肺结核化疗方案的不良反应及治疗转归情况分析. 中华疾病控制杂志, 2014, 18(7): 610-612.
14. 丁晓艳, 许卫国, 竺丽梅, 等. 175例耐多药肺结核患者治疗转归情况分析. 中国防痨杂志, 2014, 36(4): 238-243.
15. 费宗伍. 230例耐多药结核病患者的发现和治疗情况的研究. 临床医药文献电子杂志, 2014, (4): 522-523.
16. 郭苏珊. 75例耐多药肺结核治疗副作用及转归分析. 现代医院, 2015, (3): 68-69,72.
17. 屈亚虹, 朱宁, 马振亚, 等. 开封市耐多药肺结核治疗管理效果及影响因素分析. 中国防痨杂志, 2015, 37(1): 97-99.
18. 张海清, 孙建胜, 吴云亮, 等. 128例耐多药肺结核患者的转归分析. 徐州医学院学报, 2015, (8): 534-536.
19. 田晓梅, 石峰, 王晓林, 等. 宁夏耐多药/广泛耐药肺结核患者的发现及治疗效果评价. 宁夏医学杂志, 2015, 37(4): 364-366.
20. 马俊锋, 王小平, 陆峰, 等. 南通市全球基金耐多药结核病项目患者治疗情况分析. 南京医科大学学报(自然科学版), 2015, 35(5): 757-760.
21. 李莉, 孙建胜, 吴云亮. 徐州市完成全球基金耐多药结核病项目全程治疗的耐多药结核病患者治疗效果的影响因素分析. 实用心脑肺血管病杂志, 2015, (7): 50-54.
22. 张志进. 如皋市耐多药肺结核患者发现, 治疗转归情况分析. 江苏预防医学, 2016, 27(4): 498-499.
23. 刘凡平, 张晨钰, 王云, 等. 全球基金标准化疗方案治疗耐多药肺结核临床疗效评价. 河北医药, 2016, 38(7): 1060-1062.
24. 周美兰, 杜义祥, 王坚杰, 等. 武汉市耐多药肺结核患者防治模式效果分析. 中国防痨杂志, 2016, 38(11): 918-924.
25. 代晓琦, 阮云洲, 李仁忠, 等. “医防合作”模式下实施DOT对耐多药肺结核患者不同治疗转归的分析. 中国防痨杂志, 2016, 38(11): 929-933.
26. 易恒仲, 罗丹霖, 唐志冈, 等. 湖南省全球基金耐多药结核病项目患者治疗情况分析. 中国热带医学, 2017, 17(3): 244-247.
27. Lu P, Liu Q, Martinez L, et al. Time to sputum culture conversion and treatment outcome of patients with multidrug-resistant tuberculosis: a prospective cohort study from urban China. Eur Respir J, 2017, 49(3): 1601558.
28. Alene KA, Yi H, Viney K, et al. Treatment outcomes of patients with multidrug-resistant and extensively drug resistant tuberculosis in Hunan province, China. BMC Infect Dis, 2017, 17(1): 573.
29. 林彬, 杨芳玲, 王先化, 等. 克拉玛依市与昌吉州耐多药肺结核转归分析. 预防医学论坛, 2017, 23(2): 107-108,111.
30. Xu C, Pang Y, Li R, et al. Clinical outcome of multidrug-resistant tuberculosis patients receiving standardized second-line treatment regimen in China. J Infect, 2018, 76(4): 348-353.
31. Lv L, Li T, Xu K, et al. Sputum bacteriology conversion and treatment outcome of patients with multidrug-resistant tuberculosis. Infect Drug Resist, 2018, 11: 147-154.
32. Zhang L, Meng Q, Chen S, et al. Treatment outcomes of multidrug-resistant tuberculosis patients in Zhejiang, China, 2009-2013. Clin Microbiol Infect, 2018, 24(4): 381-388.
33. Fan YM, Ding SP, Bao ZJ, et al. Prognostic factors for treatment success in patients with multidrug-resistant tuberculosis in China. Int J Tuberc Lung Dis, 2018, 22(3): 300-305.
34. 包昌琳, 易恒仲, 唐益, 等. 耐多药肺结核患者化学治疗疗效及其影响因素分析. 中国防痨杂志, 2018, 40(5): 525-530.
35. 陈壮濠, 林健雄, 李鸿槟, 等. 汕头市耐多药结核病患者治疗情况分析. 临床肺科杂志, 2018, 23(10): 1850-1853.
36. Chen Y, Yuan Z, Shen X, et al. Time to multidrug-resistant tuberculosis treatment initiation in association with treatment outcomes in Shanghai, China. Antimicrob Agents Chemother, 2018, 62(4): e02259-17.
37. Li Q, Shi CX, Lu M, et al. Treatment outcomes of multidrug-resistant tuberculosis in Hangzhou, China, 2011 to 2015. Medicine (Baltimore), 2020, 99(30): e21296.
38. Zheng XB, Diwan VK, Zhao Q, et al. Treatment quality and outcome for multidrug-resistant tuberculosis patients in four regions of China: a cohort study. Infect Dis Poverty, 2020, 9(1): 97.
39. 蔡春葵, 杨连军, 王申莲, 等. 316例耐多药肺结核患者的治疗结果分析. 中国医药指南, 2020, 18(22): 41-42.
40. 简丽萍, 郭子玉, 邓笑媚, 等. 耐多药肺结核疗效影响因素的研究. 中国医药科学, 2020, 10(13): 191-194.
41. Liu Q, Yang D, Qiu B, et al. Drug resistance gene mutations and treatment outcomes in MDR-TB: a prospective study in Eastern China. PLoS Negl Trop Dis, 2021, 15(1): e0009068.
42. Zhang MW, Zhou L, Zhang Y, et al. Treatment outcomes of patients with multidrug and extensively drug-resistant tuberculosis in Zhejiang, China. Eur J Med Res, 2021, 26(1): 31.
43. 张梦娴, 杨成凤, 叶建君, 等. 1447例耐多药肺结核患者治疗转归队列分析. 公共卫生与预防医学, 2020, 31(3): 68-72.
44. Arnold A, Cooke GS, Kon OM, et al. Drug resistant TB: UK multicentre study (DRUMS): treatment, management and outcomes in London and West Midlands 2008-2014. J Infect, 2017, 74(3): 260-271.
45. Riccardi N, Saderi L, Borroni E, et al. Therapeutic strategies and outcomes of MDR and pre-XDR-TB in Italy: a nationwide study. Int J Tuberc Lung Dis, 2021, 25(5): 395-399.
46. Henry B, Revest M, Dournon N, et al. Preliminary favorable outcome for medically and surgically managed extensively drug-resistant tuberculosis, France, 2009-2014. Emerg Infect Dis, 2016, 22(3): 518-521.
47. Eshetie S, Alebel A, Wagnew F, et al. Current treatment of multidrug resistant tuberculosis in Ethiopia: an aggregated and individual patients' data analysis for outcome and effectiveness of the current regimens. BMC Infect Dis, 2018, 18(1): 486.
48. Alemu A, Bitew ZW, Worku T. Poor treatment outcome and its predictors among drug-resistant tuberculosis patients in Ethiopia: a systematic review and meta-analysis. Int J Infect Dis, 2020, 98: 420-439.
49. Alene KA, Viney K, McBryde ES, et al. Treatment outcomes in patients with multidrug-resistant tuberculosis in north-west Ethiopia. Trop Med Int Health, 2017, 22(3): 351-362.
50. Ahmed A, Mekonnen D, Shiferaw AM, et al. Incidence and determinants of tuberculosis infection among adult patients with HIV attending HIV care in north-east Ethiopia: a retrospective cohort study. BMJ Open, 2018, 8(2): e016961.
51. 中华人民共和国国务院办公厅. 全国结核病防治规划(2011-2015). Available at: http://www.gov.cn/zwgk/2011-12/06/content_2012869.htm.
52. 中华人民共和国国务院办公厅. 《“十三五”全国结核病防治规划》. Available at: http://www.gov.cn/xinwen/2017-02/16/content_5168549.htm.
53. 邝浩斌, 谢育红, 冯治宇, 等. 2014-2019年广州市耐多药肺结核管理策略实施效果分析. 中国防痨杂志, 2021, 43(2): 113-118.
54. 赵秀娟, 刘琳, 吴兴勇, 等. 海南省369例耐多药肺结核患者流行病学特征分析. 海南医学院学报, 2021. DOI: 10.13210/j.cnki.jhmu.20210413.002.
55. 王云霞, 郑娟娟, 张娟娟, 等. 2011-2018年宝安区肺结核患者耐多药的影响因素分析. 预防医学, 2021, 33(7): 701-703.
56. 全国第五次结核病流行病学抽样调查技术指导组, 全国第五次结核病流行病学抽样调查办公室. 2010年全国第五次结核病流行病学抽样调查报告. 中国防痨杂志, 2012, 34(8): 485-508.
57. 陕俊玲, 薛王谦, 韩亚男. 涂阳肺结核139例患者分枝杆菌培养及药敏分析. 中国药物与临床, 2013, 13(z1): 10-11.
58. 李秀杰. 172例耐多药结核病患者特征及治疗转归的影响因素分析. 中国现代医生, 2019, 57(7): 30-32.
59. 李雪, 李楠楠, 任斐, 等. 耐多药肺结核合并糖尿病的临床特点及治疗结局. 中国热带医学, 2021.
60. 周银发, 张山鹰, 柳珍妮, 等. 242例耐多药结核病患者特征及治疗转归的影响因素分析. 中国防痨杂志, 2017, 39(11): 1218-1222.

Previous Article
Pay-for-performance for primary care physicians: a systematic review
Next Article
Clinical practice guidelines of bronchoalveolar lavage: a methodological quality study

Chinese Journal of Evidence-Based Medicine

Treatment outcomes of multidrug-resistant tuberculosis patients in China: a meta-analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content